MCID: MCS004
MIFTS: 47

Mucosal Melanoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Mucosal Melanoma

MalaCards integrated aliases for Mucosal Melanoma:

Name: Mucosal Melanoma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050929
UMLS 73 C3898222

Summaries for Mucosal Melanoma

Disease Ontology : 12 A melanoma that has material basis in melanocytes located in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.

MalaCards based summary : Mucosal Melanoma is related to malignant skin fibrous histiocytoma and melanoma. An important gene associated with Mucosal Melanoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Phospholipase-C Pathway and fMLP Pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include mucosal membranes lining the respiratory, endothelial and lung, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 76 Mucosal melanoma is a rare cutaneous condition characterized by a melanoma of the mucous... more...

Related Diseases for Mucosal Melanoma

Diseases related to Mucosal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 malignant skin fibrous histiocytoma 30.1 KIT NRAS
2 melanoma 29.6 BRAF MAGEC1 MITF NRAS
3 skin melanoma 25.9 BRAF GNA11 GNAQ KIT MITF NRAS
4 mucositis 10.7
5 ovarian melanoma 10.6 KIT NRAS
6 amelanotic melanoma 10.6 BRAF KIT
7 conventional fibrosarcoma 10.6 KIT NRAS
8 erdheim-chester disease 10.5 BRAF NRAS
9 congenital mesoblastic nephroma 10.5 KIT NRAS
10 core binding factor acute myeloid leukemia 10.4 KIT NRAS
11 malignant dermis tumor 10.4 KIT NRAS
12 phakomatosis cesioflammea 10.4 GNA11 GNAQ
13 intraocular melanoma 10.4 GNA11 GNAQ
14 spermatocytoma 10.4 KIT MAGEC1
15 plexiform schwannoma 10.3 KIT NF1
16 pilocytic astrocytoma of cerebellum 10.2 BRAF NF1
17 neurofibromatosis, type i 10.2 KIT NF1
18 leopard syndrome 10.2 BRAF NF1
19 myelodysplastic myeloproliferative cancer 10.2 NF1 NRAS
20 pulmonic stenosis 10.1 BRAF NF1
21 sensory system cancer 10.1 GNA11 GNAQ
22 cutaneous ganglioneuroma 10.1 KIT MITF
23 breast angiosarcoma 10.0 KIT MITF
24 malignant conjunctival melanoma 10.0 GNA11 GNAQ NRAS
25 melanomatosis 10.0 GNA11 GNAQ NRAS
26 conjunctival cancer 10.0 GNA11 GNAQ NRAS
27 meningeal melanomatosis 10.0 GNA11 GNAQ NRAS
28 meningeal melanocytoma 10.0 GNA11 GNAQ NRAS
29 sinusitis 10.0
30 gastric adenocarcinoma 10.0 BRAF KIT NRAS
31 dowling-degos disease 1 10.0 KIT MITF
32 neurilemmoma 10.0 KIT NF1
33 myeloma, multiple 9.9 BRAF MAGEC1 NRAS
34 gastrointestinal stromal tumor 9.9 BRAF KIT NF1
35 noonan syndrome 1 9.8 BRAF NF1 NRAS
36 organ system benign neoplasm 9.8 KIT NF1
37 angiomyolipoma 9.8 KIT MITF
38 juvenile myelomonocytic leukemia 9.8 BRAF NF1 NRAS
39 piebald trait 9.8 KIT MITF
40 lung cancer susceptibility 3 9.7 BRAF NRAS TERT
41 nervous system cancer 9.7 GNA11 GNAQ NF1
42 mast cell disease 9.7 KIT MITF
43 cell type cancer 9.6 KIT MITF NRAS
44 li-fraumeni syndrome 9.6
45 psoriasis 2 9.6
46 psoriasis 7 9.6
47 li-fraumeni syndrome 2 9.6
48 psoriasis 11 9.6
49 psoriasis 13 9.6
50 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.6

Graphical network of the top 20 diseases related to Mucosal Melanoma:



Diseases related to Mucosal Melanoma

Symptoms & Phenotypes for Mucosal Melanoma

MGI Mouse Phenotypes related to Mucosal Melanoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.19 GNAQ GNA11 BRAF NF1 MITF KIT
2 growth/size/body region MP:0005378 10.18 BRAF GNAQ GNA11 MITF KIT NF1
3 behavior/neurological MP:0005386 10.16 BRAF GNA11 MITF KIT GNAQ NRAS
4 hematopoietic system MP:0005397 10.16 GNAQ GNA11 BRAF KIT NF1 MITF
5 homeostasis/metabolism MP:0005376 10.15 BRAF GNAQ GNA11 MITF KIT NRAS
6 craniofacial MP:0005382 10.14 GNAQ GNA11 BRAF NF1 MITF KIT
7 immune system MP:0005387 10.14 GNAQ GNA11 BRAF KIT NF1 MITF
8 cardiovascular system MP:0005385 10.08 GNA11 BRAF KIT GNAQ NRAS NF1
9 mortality/aging MP:0010768 10.08 BRAF GNAQ GNA11 MITF KIT NRAS
10 integument MP:0010771 10.07 GNAQ GNA11 BRAF KIT NF1 MITF
11 hearing/vestibular/ear MP:0005377 10.04 GNAQ GNA11 BRAF KIT NF1 MITF
12 digestive/alimentary MP:0005381 9.99 BRAF KIT TERT NRAS NF1
13 limbs/digits/tail MP:0005371 9.99 GNAQ GNA11 KIT NF1 MITF NRAS
14 normal MP:0002873 9.97 GNAQ GNA11 BRAF NF1 MITF KIT
15 nervous system MP:0003631 9.95 BRAF GNA11 MITF KIT GNAQ TERT
16 liver/biliary system MP:0005370 9.89 GNA11 BRAF KIT NRAS NF1
17 pigmentation MP:0001186 9.87 GNAQ GNA11 BRAF NF1 MITF KIT
18 muscle MP:0005369 9.85 GNA11 BRAF KIT GNAQ NF1
19 neoplasm MP:0002006 9.83 BRAF KIT NRAS NF1 TERT
20 renal/urinary system MP:0005367 9.65 GNA11 BRAF KIT GNAQ NF1
21 respiratory system MP:0005388 9.63 GNAQ GNA11 BRAF KIT NF1 TERT
22 skeleton MP:0005390 9.56 GNAQ GNA11 BRAF NF1 MITF KIT
23 vision/eye MP:0005391 9.02 BRAF MITF KIT NRAS NF1

Drugs & Therapeutics for Mucosal Melanoma

Drugs for Mucosal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
3
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
4
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
6
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
7
Nicotinamide Approved, Investigational, Nutraceutical Phase 3 98-92-0 936
8 Albumin-Bound Paclitaxel Phase 3,Phase 2
9 Antimitotic Agents Phase 3,Phase 2
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
11 Micronutrients Phase 3
12 Nicotinic Acids Phase 3
13 Protein Kinase Inhibitors Phase 3,Phase 2
14 Trace Elements Phase 3
15 Vitamin B Complex Phase 3
16 Vitamins Phase 3
17 Antibodies Phase 3,Phase 2
18 Immunoglobulins Phase 3,Phase 2
19 Antibodies, Monoclonal Phase 3,Phase 2
20 Anti-Infective Agents Phase 3,Phase 2
21 Antiviral Agents Phase 3,Phase 2
22 Interferon-alpha Phase 3,Phase 2
23 interferons Phase 3,Phase 2,Phase 1
24 Folate Nutraceutical Phase 3
25 Vitamin B3 Nutraceutical Phase 3
26 Vitamin B9 Nutraceutical Phase 3
27
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
28
nivolumab Approved Phase 2 946414-94-4
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
31
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
32
Menthol Approved Phase 2 2216-51-5 16666
33
Everolimus Approved Phase 2 159351-69-6 6442177
34
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
36
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
37 Imatinib Mesylate Phase 2 220127-57-1 123596
38 Angiogenesis Inhibitors Phase 2
39 Angiogenesis Modulating Agents Phase 2
40 Vaccines Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 2
42 Freund's Adjuvant Phase 2,Phase 1
43 Interferon Inducers Phase 1, Phase 2,Phase 2
44 Poly ICLC Phase 1, Phase 2,Phase 2
45 Analgesics Phase 2
46 Analgesics, Non-Narcotic Phase 2
47 Anti-HIV Agents Phase 2
48 Anti-Retroviral Agents Phase 2
49 Interleukin-2 Phase 2
50 Peripheral Nervous System Agents Phase 2

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
2 HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Recruiting NCT03435302 Phase 3 Temozolomide Plus Cisplatin;High-Dose IFN-a2b
3 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Active, not recruiting NCT02506153 Phase 3
4 A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Completed NCT01395121 Phase 2 nilotinib
5 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma Completed NCT00424515 Phase 2 Imatinib
6 Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma Completed NCT00881049 Phase 2 Imatinib (Gleevec)
7 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed NCT00577382 Phase 2 Sunitinib
8 Study of Nilotinib in Metastatic Melanoma With KIT Aberrations Completed NCT01099514 Phase 2 Nilotinib
9 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
10 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
11 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
12 The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery Recruiting NCT03178123 Phase 2
13 Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era Recruiting NCT03138642 Phase 2
14 Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Recruiting NCT03241186 Phase 2 Ipilimumab;Nivolumab;Nivolumab
15 PLX3397 KIT in Acral aNd mucOsal Melanoma Recruiting NCT02071940 Phase 2 PLX3397
16 Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma Recruiting NCT02023710 Phase 2 Paclitaxel;Carboplatin;Bevacizumab
17 Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Recruiting NCT02126579 Phase 1, Phase 2
18 Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients Recruiting NCT03190824 Phase 2 OBP-301
19 Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Recruiting NCT02748564 Phase 2
20 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Active, not recruiting NCT00700882 Phase 2 dasatinib
21 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Active, not recruiting NCT02158520 Phase 2 Nab-paclitaxel
22 Dinaciclib in Treating Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
23 Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma Active, not recruiting NCT01827111 Phase 2 ABI-007;Ipilimumab
24 Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma Not yet recruiting NCT03313206 Phase 2 Pembrolizumab
25 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Not yet recruiting NCT03220009 Phase 2
26 Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Not yet recruiting NCT03235245 Phase 2 Nivolumab + Ipilimumab;Encorafenib + Binimetinib
27 CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma Suspended NCT02129075 Phase 2
28 Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Terminated NCT01092728 Phase 2 Dasatinib
29 Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Terminated NCT01166126 Phase 2 temsirolimus;selumetinib
30 Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients Terminated NCT00706992 Phase 2
31 A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma Terminated NCT01864538 Phase 2 TH-302
32 Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) Completed NCT02180061 Phase 1
33 Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Completed NCT00798629 Phase 1
34 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Recruiting NCT02858869 Phase 1
35 Molecular Characterization of Primary Mucosal Melanoma Recruiting NCT03319693
36 A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Recruiting NCT02978443 Nivolumab;Ipilimumab

Search NIH Clinical Center for Mucosal Melanoma

Genetic Tests for Mucosal Melanoma

Anatomical Context for Mucosal Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Mucosal Melanoma:

19
Mucosal Membranes Lining The Respiratory

MalaCards organs/tissues related to Mucosal Melanoma:

41
Endothelial, Lung, Skin, Brain, Lymph Node, Testis, Tonsil

Publications for Mucosal Melanoma

Articles related to Mucosal Melanoma:

(show top 50) (show all 173)
# Title Authors Year
1
Mucosal melanoma: clinical and genetic profile. ( 29797459 )
2018
2
Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )
2018
3
Updates in the management of sinonasal mucosal melanoma. ( 29095708 )
2018
4
Mucosal Melanoma: a Literature Review. ( 29569184 )
2018
5
Anorectal mucosal melanoma. ( 29492238 )
2018
6
Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. ( 29044491 )
2018
7
Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report. ( 29535967 )
2018
8
Reply to mucosal melanoma: clinical and genetic profile. ( 29799644 )
2018
9
Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma. ( 29492677 )
2018
10
Analysis of TSC1 mutation spectrum in mucosal melanoma. ( 29185092 )
2018
11
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. ( 29748886 )
2018
12
Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. ( 29230811 )
2018
13
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma. ( 29626308 )
2018
14
A comprehensive genome-wide analysis of the long noncoding RNA expression profile in metastatic lymph nodes of oral mucosal melanoma. ( 29960071 )
2018
15
Immunotherapy in mucosal melanoma: a case report and review of the literature. ( 29707161 )
2018
16
<i>KIT, NRAS, BRAF</i> and <i>FMNL2</i> mutations in oral mucosal melanoma and a systematic review of the literature. ( 29805686 )
2018
17
Are oral mucosal nevi potential precursors for oral mucosal melanoma? ( 29501410 )
2018
18
Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. ( 29952773 )
2018
19
Genital mucosal melanoma with somatic SF3B1 R625C mutation. ( 29624176 )
2018
20
Combination therapy improves immune response and prognosis in patients with advanced oral mucosal melanoma: A clinical treatment success. ( 29958936 )
2018
21
The clinical significance of<i>c-Kit</i>mutations in metastatic oral mucosal melanoma in China. ( 29137292 )
2017
22
Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma. ( 28134726 )
2017
23
Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution. ( 29103739 )
2017
24
Mucosal Melanoma Originating From the Eustachian Tube. ( 28953148 )
2017
25
Failure patterns and prognostic factors of patients with primary mucosal melanoma of the nasal cavity and paranasal sinuses. ( 28767022 )
2017
26
Adjuvant radiotherapy in sinonasal mucosal melanoma: A retrospective analysis. ( 29150980 )
2017
27
Sinonasal mucosal melanoma: A 44-case study and literature analysis. ( 28442409 )
2017
28
Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab. ( 28497158 )
2017
29
Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases. ( 29151970 )
2017
30
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. ( 28600969 )
2017
31
Predictors of survival in head and neck mucosal melanoma. ( 28939074 )
2017
32
Treatment of Primary and Metastatic Multifocal Mucosal Melanoma of the Oral Cavity with Imatinib. ( 28868012 )
2017
33
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. ( 28485171 )
2017
34
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. ( 28056206 )
2017
35
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. ( 28092667 )
2017
36
The Tumor Suppressor p53 in Mucosal Melanoma of the Head and Neck. ( 29236030 )
2017
37
Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases. ( 28543798 )
2017
38
Clinical investigation of 38 cases of oral mucosal melanoma: A multicentre retrospective analysis in Japan. ( 28809036 )
2017
39
Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma. ( 29142805 )
2017
40
Comparative study of head and neck mucosal melanoma in 66 patients vs 226 patients with cutaneous melanoma: A survival analysis. ( 28986955 )
2017
41
Increased p16 and p53 protein expression predicts poor prognosis in mucosal melanoma. ( 28881806 )
2017
42
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. ( 28296713 )
2017
43
Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations. ( 27726232 )
2017
44
Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients. ( 28072717 )
2017
45
Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). ( 28332989 )
2017
46
Longitudinal clinicopathologic data of the progression of oral mucosal melanoma-report of 2 cases and literature review. ( 29429904 )
2017
47
A Review of the Aetiopathogenesis and Clinical and Histopathological Features of Oral Mucosal Melanoma. ( 28638859 )
2017
48
Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. ( 28494469 )
2017
49
Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma. ( 28944501 )
2017
50
Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling. ( 29410768 )
2017

Variations for Mucosal Melanoma

Expression for Mucosal Melanoma

Search GEO for disease gene expression data for Mucosal Melanoma.

Pathways for Mucosal Melanoma

Pathways related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 BRAF GNA11 KIT NRAS
2
Show member pathways
12.8 BRAF GNA11 GNAQ NRAS
3
Show member pathways
12.62 BRAF GNA11 MITF NRAS
4
Show member pathways
12.6 BRAF GNA11 GNAQ NRAS
5
Show member pathways
12.56 BRAF GNA11 GNAQ KIT NRAS
6
Show member pathways
12.55 BRAF MITF NF1 NRAS
7 12.54 BRAF KIT NF1 NRAS
8
Show member pathways
12.53 BRAF KIT NRAS TERT
9
Show member pathways
12.49 BRAF GNA11 GNAQ NRAS
10
Show member pathways
12.49 BRAF GNA11 GNAQ KIT MITF NRAS
11
Show member pathways
12.36 BRAF GNAQ KIT NF1 NRAS
12
Show member pathways
12.24 BRAF MITF NRAS
13
Show member pathways
12.1 BRAF NF1 NRAS
14
Show member pathways
12.01 BRAF GNAQ NRAS
15 11.89 BRAF GNA11 GNAQ KIT MITF NRAS
16
Show member pathways
11.87 BRAF NF1 NRAS
17
Show member pathways
11.81 BRAF GNA11 GNAQ
18 11.75 BRAF GNAQ NRAS
19 11.73 BRAF NF1 NRAS
20 11.7 BRAF GNA11 GNAQ
21 11.61 BRAF GNAQ NF1 NRAS
22 11.6 BRAF GNA11 GNAQ
23 11.55 GNA11 GNAQ NRAS
24
Show member pathways
11.46 BRAF KIT NRAS
25 11.35 NF1 NRAS
26 11.28 BRAF NRAS
27 11.26 KIT MITF
28 11.23 GNA11 GNAQ
29 11.18 GNA11 GNAQ
30 11.16 GNA11 GNAQ
31 11.16 BRAF NRAS
32 11.07 GNA11 GNAQ NRAS
33 11.03 BRAF GNA11 GNAQ NRAS
34 10.91 GNAQ NRAS
35
Show member pathways
10.8 GNA11 GNAQ

GO Terms for Mucosal Melanoma

Cellular components related to Mucosal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heterotrimeric G-protein complex GO:0005834 8.62 GNA11 GNAQ

Biological processes related to Mucosal Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 BRAF KIT MITF TERT
2 heart development GO:0007507 9.75 GNA11 GNAQ NF1
3 MAPK cascade GO:0000165 9.67 BRAF KIT NF1 NRAS
4 regulation of cell proliferation GO:0042127 9.62 BRAF KIT MITF NF1
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.57 BRAF TERT
6 response to cadmium ion GO:0046686 9.56 KIT TERT
7 melanocyte differentiation GO:0030318 9.52 KIT MITF
8 action potential GO:0001508 9.51 GNA11 GNAQ
9 G-protein coupled acetylcholine receptor signaling pathway GO:0007213 9.49 GNA11 GNAQ
10 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.48 GNA11 GNAQ
11 phototransduction, visible light GO:0007603 9.46 GNA11 GNAQ
12 entrainment of circadian clock GO:0009649 9.43 GNA11 GNAQ
13 visual learning GO:0008542 9.43 BRAF KIT NF1
14 myeloid progenitor cell differentiation GO:0002318 9.4 BRAF KIT
15 pigmentation GO:0043473 9.33 KIT MITF NF1
16 regulation of melanocyte differentiation GO:0045634 8.96 GNA11 GNAQ
17 developmental pigmentation GO:0048066 8.8 GNA11 GNAQ KIT
18 signal transduction GO:0007165 10.01 BRAF GNA11 GNAQ KIT NF1 NRAS

Molecular functions related to Mucosal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase activity GO:0003924 9.43 GNA11 GNAQ NRAS
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.16 GNA11 GNAQ
3 guanyl nucleotide binding GO:0019001 8.96 GNA11 GNAQ
4 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Mucosal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....